These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 8513845

  • 1. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
    Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.
    Eur J Clin Pharmacol; 1993; 44(4):349-55. PubMed ID: 8513845
    [Abstract] [Full Text] [Related]

  • 2. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK, Brøsen K, Hansen MG, Gram LF.
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [Abstract] [Full Text] [Related]

  • 3. The relationship between paroxetine and the sparteine oxidation polymorphism.
    Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC.
    Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L.
    Eur J Clin Pharmacol; 1986 Mar; 30(6):679-84. PubMed ID: 3533565
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS, Phillips AC, Rieutord A, Shenfield GM.
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K, Otton SV, Gram LF.
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH, Brøsen K, Gram LF.
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
    Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH.
    Eur J Clin Pharmacol; 1996 Mar; 51(3-4):289-95. PubMed ID: 9010701
    [Abstract] [Full Text] [Related]

  • 14. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K, Gram LF.
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
    Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C.
    Drug Metab Dispos; 2003 Jan; 31(1):76-87. PubMed ID: 12485956
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.